#Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers 

When a Food and Drug Administration advisory panel meets Monday to size up an Eli Lilly experimental Alzheimer’s drug, questions about safety, selection of patients for treatment, and dosing will be at the fore, documents released Thursday show.

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.

If you want to read more News articles, you can visit our News category.

Source